Exhibit 99.1 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023 AND FOR THE SIX MONTHS ENDED JUNE 30, 2024 AND 2023 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | Interim Condensed Balance Sheets as of June 30, 2024 (unaudited) and Decembe ...

This agreement will see Kadimastem acquired by a wholly-owned subsidiary of NLS Pharmaceutics. When that happens, Kadimastem investors will obtain 85% of NLSP stock. This will see the combined company operate under the Kadimastem name. That will leave the remaining 15% for NLSP investors. Alex Zwyer, CEO of NLS Pharmaceutics, said the following about the merger. The two companies expect to execute the agreement in September. This should see the deal close by the end of the year. NLSP stock is seeing heavy t ...

Group 1 - NLS Pharmaceutics (NASDAQ:NLSP) stock experienced a significant rally of 82.1% on Tuesday, with over 302 million shares traded, compared to its daily average of 6.5 million shares [1][2] - The rally occurred without any clear news from the company, indicating that speculative trading may have driven the price increase, particularly as NLSP is classified as a penny stock, making it susceptible to manipulation [2] - As of Thursday morning, NLSP stock is down 22.6%, and it has decreased by 54.2% since the beginning of the year [3]

FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR Switzerland (Jurisdiction of incorporation or organization) The Circle 6 8058 Zurich Switzerland (Address of principal executive of ices) Alexander Zwyer Chief Executive Officer Tel: +41 44 512 21 50 contact@nls-pharma.com The Circle 6, Postfach 8058 Zurich Switzerlan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2023 (Report No. 2) Commission file number: 001-39957 SIGNATURES NLS PHARMACEUTICS LTD. (Translation of registrant's name into English) The Circle 6 8058 Zurich, Switzerland (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under ...

FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 001-39957 NLS PHARMACEUTICS LTD. (Exact name of registrant ...

| Unaudited Interim Condensed Balance Sheets as of June 30, 2022 and December 31, 2021 | 1 | | --- | --- | | Unaudited Interim Condensed Statements of Operating and Comprehensive Loss for the Six Months Ended June 30, 2022 | 2 | | and 2021 | | | Unaudited Interim Condensed Statements of Changes in Equity for the Six Months Ended June 30, 2022 and 2021 | 3 | | Unaudited Interim Condensed Statements of Cash Flows for the Six Months Ended June 30, 2022 and 2021 | 4 | | Notes to the Unaudited Interim Condensed ...

FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 001-39957 NLS PHARMACEUTICS LTD. (Exact name of registrant ...

Exhibit 99.1 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS | Unaudited Interim Condensed Balance Sheets as of June 30, 2021 and December 31, 2020 | 3 | | --- | --- | | Unaudited Interim Condensed Statements of Operating and Comprehensive Loss for the Six Months Ended June 30, 2021 | 4 | | and 2020 | | | Unaudited Interim Condensed Statements of Changes i ...

FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 001-39957 NLS PHARMACEUTICS LTD. (Exact name of registrant ...